| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vasodilation | 25 | 2016 | 181 | 3.610 |
Why?
|
| Potassium Channels, Tandem Pore Domain | 14 | 2019 | 35 | 3.540 |
Why?
|
| Middle Cerebral Artery | 16 | 2013 | 115 | 3.230 |
Why?
|
| Cerebrovascular Circulation | 23 | 2019 | 476 | 3.020 |
Why?
|
| Endothelium, Vascular | 20 | 2013 | 486 | 2.680 |
Why?
|
| Cerebral Arteries | 15 | 2016 | 83 | 2.440 |
Why?
|
| Gastrointestinal Microbiome | 14 | 2025 | 810 | 2.290 |
Why?
|
| Muscle, Smooth, Vascular | 16 | 2011 | 238 | 2.080 |
Why?
|
| Sleep Apnea, Obstructive | 6 | 2023 | 234 | 1.660 |
Why?
|
| Rats | 48 | 2023 | 3607 | 1.560 |
Why?
|
| Vasoconstriction | 15 | 2020 | 104 | 1.530 |
Why?
|
| Rats, Long-Evans | 27 | 2018 | 102 | 1.450 |
Why?
|
| Nitric Oxide | 13 | 2013 | 470 | 1.290 |
Why?
|
| Blood Pressure | 15 | 2022 | 1402 | 1.270 |
Why?
|
| Biological Factors | 7 | 2013 | 27 | 1.250 |
Why?
|
| Hypertension | 11 | 2023 | 1398 | 1.160 |
Why?
|
| Sleep | 4 | 2025 | 373 | 1.020 |
Why?
|
| Brain Injuries | 7 | 2023 | 716 | 1.000 |
Why?
|
| Cerebral Cortex | 8 | 2012 | 484 | 0.980 |
Why?
|
| Stroke | 7 | 2025 | 1082 | 0.960 |
Why?
|
| Brain | 12 | 2025 | 3194 | 0.930 |
Why?
|
| Animals | 75 | 2025 | 34854 | 0.930 |
Why?
|
| Endothelin-1 | 3 | 2020 | 43 | 0.890 |
Why?
|
| Adenosine Triphosphate | 8 | 2019 | 275 | 0.850 |
Why?
|
| Vasodilator Agents | 6 | 2013 | 208 | 0.820 |
Why?
|
| Brain Ischemia | 4 | 2013 | 278 | 0.800 |
Why?
|
| Aging | 7 | 2025 | 1254 | 0.800 |
Why?
|
| Dysbiosis | 6 | 2025 | 139 | 0.780 |
Why?
|
| White Matter | 4 | 2025 | 211 | 0.740 |
Why?
|
| Arterioles | 7 | 2012 | 40 | 0.720 |
Why?
|
| Disease Models, Animal | 15 | 2025 | 4690 | 0.700 |
Why?
|
| Fecal Microbiota Transplantation | 2 | 2020 | 107 | 0.670 |
Why?
|
| rho-Associated Kinases | 3 | 2019 | 51 | 0.660 |
Why?
|
| Fatty Acids, Volatile | 1 | 2020 | 46 | 0.660 |
Why?
|
| Blood-Brain Barrier | 1 | 2021 | 156 | 0.640 |
Why?
|
| Cognitive Dysfunction | 3 | 2020 | 315 | 0.640 |
Why?
|
| Cognition | 3 | 2021 | 811 | 0.610 |
Why?
|
| NG-Nitroarginine Methyl Ester | 13 | 2013 | 59 | 0.600 |
Why?
|
| Pulmonary Artery | 4 | 2020 | 463 | 0.600 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2020 | 231 | 0.570 |
Why?
|
| Potassium | 4 | 2017 | 275 | 0.570 |
Why?
|
| Membrane Potentials | 5 | 2017 | 303 | 0.560 |
Why?
|
| Arachidonic Acid | 6 | 2013 | 67 | 0.530 |
Why?
|
| Reperfusion Injury | 2 | 2013 | 110 | 0.520 |
Why?
|
| Neuroimaging | 1 | 2020 | 375 | 0.510 |
Why?
|
| Cyclic GMP | 3 | 2009 | 95 | 0.510 |
Why?
|
| Receptors, Purinergic P2 | 4 | 1999 | 17 | 0.500 |
Why?
|
| Period Circadian Proteins | 1 | 2016 | 25 | 0.490 |
Why?
|
| Male | 56 | 2025 | 65014 | 0.480 |
Why?
|
| In Vitro Techniques | 12 | 2006 | 862 | 0.480 |
Why?
|
| Cerebral Small Vessel Diseases | 1 | 2015 | 10 | 0.480 |
Why?
|
| Receptors, Endothelin | 1 | 2014 | 10 | 0.450 |
Why?
|
| Circadian Clocks | 1 | 2016 | 82 | 0.450 |
Why?
|
| Phospholipases A | 2 | 2006 | 36 | 0.450 |
Why?
|
| Basilar Artery | 2 | 2010 | 26 | 0.450 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2015 | 83 | 0.450 |
Why?
|
| Wounds, Nonpenetrating | 3 | 2003 | 221 | 0.440 |
Why?
|
| Potassium Channels | 6 | 2006 | 161 | 0.430 |
Why?
|
| Rats, Inbred WKY | 5 | 2022 | 48 | 0.420 |
Why?
|
| Rats, Inbred SHR | 5 | 2022 | 58 | 0.410 |
Why?
|
| Purinergic P2Y Receptor Agonists | 1 | 2013 | 4 | 0.410 |
Why?
|
| Peroxynitrous Acid | 1 | 2013 | 8 | 0.410 |
Why?
|
| Circadian Rhythm | 1 | 2016 | 316 | 0.400 |
Why?
|
| Gene Expression Regulation | 2 | 2014 | 2442 | 0.390 |
Why?
|
| Dose-Response Relationship, Drug | 8 | 2013 | 1671 | 0.390 |
Why?
|
| Microcirculation | 1 | 2013 | 117 | 0.390 |
Why?
|
| Hypertension, Pulmonary | 2 | 2014 | 463 | 0.380 |
Why?
|
| Mice | 22 | 2025 | 18509 | 0.380 |
Why?
|
| Potassium Chloride | 5 | 2011 | 48 | 0.370 |
Why?
|
| Calcium | 8 | 2019 | 1080 | 0.370 |
Why?
|
| alpha-Linolenic Acid | 2 | 2010 | 15 | 0.360 |
Why?
|
| Arginine | 5 | 2005 | 343 | 0.350 |
Why?
|
| Potassium Channels, Calcium-Activated | 1 | 2010 | 12 | 0.350 |
Why?
|
| Aorta | 2 | 2011 | 552 | 0.340 |
Why?
|
| Mice, Knockout | 8 | 2017 | 3868 | 0.340 |
Why?
|
| Hypothalamus | 1 | 2012 | 212 | 0.330 |
Why?
|
| Vasomotor System | 3 | 2006 | 21 | 0.320 |
Why?
|
| Penicillamine | 4 | 2002 | 6 | 0.310 |
Why?
|
| Enzyme Inhibitors | 9 | 2005 | 589 | 0.310 |
Why?
|
| Mice, Inbred C57BL | 12 | 2025 | 4758 | 0.310 |
Why?
|
| Neuroprotective Agents | 1 | 2010 | 161 | 0.300 |
Why?
|
| Aorta, Thoracic | 2 | 2013 | 540 | 0.300 |
Why?
|
| DNA | 1 | 2014 | 1479 | 0.300 |
Why?
|
| Indomethacin | 5 | 2013 | 82 | 0.290 |
Why?
|
| Carbon Dioxide | 2 | 2000 | 275 | 0.290 |
Why?
|
| Hypotension | 2 | 2021 | 185 | 0.290 |
Why?
|
| Erythropoietin | 1 | 2008 | 107 | 0.270 |
Why?
|
| Epoprostenol | 2 | 2013 | 44 | 0.260 |
Why?
|
| Nitric Oxide Synthase Type III | 6 | 2013 | 190 | 0.260 |
Why?
|
| TRPV Cation Channels | 1 | 2006 | 46 | 0.250 |
Why?
|
| Heme Oxygenase (Decyclizing) | 1 | 2006 | 9 | 0.250 |
Why?
|
| Aminolevulinic Acid | 1 | 2006 | 9 | 0.250 |
Why?
|
| Carbon Monoxide | 1 | 2006 | 25 | 0.250 |
Why?
|
| Electroencephalography | 2 | 2025 | 908 | 0.240 |
Why?
|
| Potassium Channel Blockers | 5 | 2013 | 84 | 0.230 |
Why?
|
| Uridine Triphosphate | 5 | 2008 | 10 | 0.230 |
Why?
|
| Glyburide | 3 | 2000 | 23 | 0.220 |
Why?
|
| Hydrogen Peroxide | 1 | 2005 | 124 | 0.220 |
Why?
|
| Hypoglycemia | 2 | 1998 | 183 | 0.220 |
Why?
|
| Receptors, Aryl Hydrocarbon | 1 | 2025 | 67 | 0.220 |
Why?
|
| Nitric Oxide Synthase | 6 | 2001 | 173 | 0.220 |
Why?
|
| Histamine | 2 | 2023 | 49 | 0.210 |
Why?
|
| Histamine Release | 1 | 2023 | 9 | 0.210 |
Why?
|
| Germ-Free Life | 2 | 2021 | 61 | 0.210 |
Why?
|
| Inflammation | 3 | 2023 | 1522 | 0.210 |
Why?
|
| Mast Cells | 2 | 2023 | 67 | 0.210 |
Why?
|
| Myocytes, Smooth Muscle | 2 | 2019 | 189 | 0.210 |
Why?
|
| Cytokines | 3 | 2020 | 1365 | 0.210 |
Why?
|
| Cerebellum | 1 | 2007 | 464 | 0.200 |
Why?
|
| Signal Transduction | 2 | 2014 | 4720 | 0.200 |
Why?
|
| Vasoconstrictor Agents | 3 | 2019 | 141 | 0.200 |
Why?
|
| Leukoaraiosis | 1 | 2022 | 4 | 0.190 |
Why?
|
| Vascular Resistance | 1 | 2003 | 195 | 0.190 |
Why?
|
| Laser-Doppler Flowmetry | 3 | 2010 | 62 | 0.180 |
Why?
|
| Potassium Channels, Inwardly Rectifying | 2 | 1998 | 39 | 0.180 |
Why?
|
| Microglia | 2 | 2025 | 138 | 0.180 |
Why?
|
| Muscle Contraction | 2 | 2000 | 154 | 0.170 |
Why?
|
| Neuropeptide Y | 1 | 2001 | 35 | 0.170 |
Why?
|
| Blotting, Western | 3 | 2014 | 1080 | 0.170 |
Why?
|
| Mental Status and Dementia Tests | 1 | 2020 | 24 | 0.170 |
Why?
|
| Metabolome | 2 | 2021 | 324 | 0.170 |
Why?
|
| Ileum | 1 | 2021 | 130 | 0.170 |
Why?
|
| Endothelium | 1 | 2020 | 64 | 0.160 |
Why?
|
| Environment | 1 | 2021 | 148 | 0.160 |
Why?
|
| Glucose Metabolism Disorders | 1 | 2019 | 5 | 0.160 |
Why?
|
| Central Nervous System Diseases | 1 | 2020 | 109 | 0.160 |
Why?
|
| Fasting | 1 | 2021 | 302 | 0.160 |
Why?
|
| Extracellular Vesicles | 1 | 2020 | 58 | 0.160 |
Why?
|
| Verbal Learning | 1 | 2019 | 71 | 0.150 |
Why?
|
| Feces | 2 | 2020 | 753 | 0.150 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2020 | 210 | 0.150 |
Why?
|
| Leukocytes | 1 | 2020 | 209 | 0.150 |
Why?
|
| Nitric Oxide Donors | 2 | 2013 | 20 | 0.150 |
Why?
|
| Peptides | 2 | 2019 | 844 | 0.150 |
Why?
|
| Prebiotics | 1 | 2018 | 28 | 0.150 |
Why?
|
| Regional Blood Flow | 2 | 2010 | 212 | 0.150 |
Why?
|
| Reperfusion | 1 | 1998 | 26 | 0.150 |
Why?
|
| Quinoxalines | 4 | 2002 | 38 | 0.140 |
Why?
|
| Acetates | 1 | 2018 | 80 | 0.140 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2025 | 3853 | 0.140 |
Why?
|
| Homeostasis | 2 | 1999 | 722 | 0.140 |
Why?
|
| Phenylephrine | 2 | 2019 | 40 | 0.140 |
Why?
|
| Adenosine Diphosphate | 1 | 1997 | 55 | 0.140 |
Why?
|
| Antihypertensive Agents | 1 | 2020 | 430 | 0.130 |
Why?
|
| Hypoglycemic Agents | 2 | 1999 | 482 | 0.130 |
Why?
|
| Atherosclerosis | 1 | 2025 | 1006 | 0.130 |
Why?
|
| Blood Flow Velocity | 3 | 2007 | 440 | 0.130 |
Why?
|
| Immunohistochemistry | 2 | 2014 | 1718 | 0.130 |
Why?
|
| Memory | 1 | 2020 | 356 | 0.130 |
Why?
|
| Interleukin-1beta | 1 | 2017 | 163 | 0.130 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2020 | 605 | 0.130 |
Why?
|
| Rats, Inbred Strains | 4 | 1998 | 219 | 0.130 |
Why?
|
| Charybdotoxin | 3 | 2001 | 8 | 0.130 |
Why?
|
| Microbiota | 1 | 2022 | 434 | 0.130 |
Why?
|
| Intracranial Pressure | 4 | 1999 | 212 | 0.130 |
Why?
|
| 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid | 2 | 2019 | 33 | 0.130 |
Why?
|
| Dyslipidemias | 1 | 2019 | 241 | 0.130 |
Why?
|
| Receptors, Adrenergic, alpha-2 | 1 | 1996 | 5 | 0.130 |
Why?
|
| Bacteria | 1 | 2020 | 522 | 0.130 |
Why?
|
| Genotype | 2 | 2014 | 2703 | 0.120 |
Why?
|
| Intestines | 1 | 2020 | 606 | 0.120 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2014 | 826 | 0.120 |
Why?
|
| Polyamines | 1 | 1996 | 31 | 0.120 |
Why?
|
| Receptors, Adrenergic, alpha | 1 | 1995 | 8 | 0.120 |
Why?
|
| Probiotics | 1 | 2018 | 226 | 0.120 |
Why?
|
| Coronary Disease | 1 | 2019 | 685 | 0.120 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2014 | 541 | 0.120 |
Why?
|
| Fluorescent Dyes | 3 | 2020 | 264 | 0.120 |
Why?
|
| Endothelial Cells | 3 | 2020 | 526 | 0.120 |
Why?
|
| Action Potentials | 3 | 2019 | 495 | 0.120 |
Why?
|
| Hernias, Diaphragmatic, Congenital | 1 | 2020 | 426 | 0.120 |
Why?
|
| Cerebrovascular Disorders | 1 | 2016 | 119 | 0.110 |
Why?
|
| Femoral Artery | 1 | 1996 | 168 | 0.110 |
Why?
|
| Phospholipases A2 | 2 | 2006 | 36 | 0.110 |
Why?
|
| Cricetinae | 2 | 2009 | 381 | 0.110 |
Why?
|
| Gene Expression | 2 | 2009 | 1563 | 0.110 |
Why?
|
| Humans | 17 | 2025 | 132247 | 0.110 |
Why?
|
| Polysomnography | 1 | 2015 | 155 | 0.110 |
Why?
|
| Barium Compounds | 3 | 1999 | 5 | 0.110 |
Why?
|
| Receptors, Purinergic P2Y2 | 3 | 1999 | 17 | 0.110 |
Why?
|
| Time Factors | 4 | 2021 | 6451 | 0.110 |
Why?
|
| Chlorides | 3 | 1999 | 103 | 0.110 |
Why?
|
| Catecholamines | 1 | 1994 | 52 | 0.110 |
Why?
|
| Acute Lung Injury | 1 | 2014 | 68 | 0.110 |
Why?
|
| Cyclooxygenase Inhibitors | 2 | 2005 | 53 | 0.100 |
Why?
|
| Blood Glucose | 1 | 1998 | 1121 | 0.100 |
Why?
|
| Ventricular Function, Right | 1 | 2014 | 119 | 0.100 |
Why?
|
| Calcimycin | 1 | 2013 | 21 | 0.100 |
Why?
|
| Docosahexaenoic Acids | 1 | 2013 | 66 | 0.100 |
Why?
|
| Respiration | 1 | 2013 | 123 | 0.100 |
Why?
|
| Amacrine Cells | 1 | 2013 | 43 | 0.100 |
Why?
|
| Hyperoxia | 1 | 2014 | 130 | 0.100 |
Why?
|
| Superoxide Dismutase | 3 | 2005 | 176 | 0.090 |
Why?
|
| Pia Mater | 2 | 2003 | 10 | 0.090 |
Why?
|
| 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester | 1 | 2011 | 5 | 0.090 |
Why?
|
| Calcium Channel Agonists | 1 | 2011 | 11 | 0.090 |
Why?
|
| Trachea | 1 | 2013 | 210 | 0.090 |
Why?
|
| Obesity | 2 | 2022 | 2398 | 0.090 |
Why?
|
| Fura-2 | 2 | 2001 | 12 | 0.090 |
Why?
|
| Hypoxia | 1 | 2013 | 259 | 0.090 |
Why?
|
| Depression | 1 | 2020 | 1350 | 0.090 |
Why?
|
| S-Nitroso-N-Acetylpenicillamine | 2 | 2001 | 2 | 0.090 |
Why?
|
| Catalase | 2 | 2001 | 64 | 0.080 |
Why?
|
| Rats, Sprague-Dawley | 3 | 2020 | 1224 | 0.080 |
Why?
|
| Oxadiazoles | 2 | 2002 | 25 | 0.080 |
Why?
|
| Hypercapnia | 2 | 2001 | 23 | 0.080 |
Why?
|
| Stress, Mechanical | 2 | 2001 | 170 | 0.080 |
Why?
|
| Free Radical Scavengers | 2 | 2001 | 58 | 0.080 |
Why?
|
| Thionucleotides | 2 | 2002 | 23 | 0.080 |
Why?
|
| Electrophysiology | 2 | 2013 | 268 | 0.080 |
Why?
|
| Cell Count | 1 | 2010 | 234 | 0.080 |
Why?
|
| Large-Conductance Calcium-Activated Potassium Channels | 1 | 2010 | 22 | 0.080 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2010 | 66 | 0.080 |
Why?
|
| Barium | 1 | 2009 | 17 | 0.080 |
Why?
|
| Cricetulus | 1 | 2009 | 93 | 0.080 |
Why?
|
| CHO Cells | 1 | 2009 | 158 | 0.080 |
Why?
|
| RNA, Ribosomal, 16S | 2 | 2023 | 394 | 0.080 |
Why?
|
| Glucose | 1 | 1994 | 871 | 0.080 |
Why?
|
| Cyclic GMP-Dependent Protein Kinases | 1 | 2009 | 13 | 0.080 |
Why?
|
| Chronic Disease | 1 | 2013 | 1233 | 0.070 |
Why?
|
| Cloning, Molecular | 1 | 2009 | 811 | 0.070 |
Why?
|
| Cell Survival | 1 | 2010 | 868 | 0.070 |
Why?
|
| Kinetics | 2 | 2002 | 1130 | 0.070 |
Why?
|
| Receptors, Erythropoietin | 1 | 2008 | 13 | 0.070 |
Why?
|
| Serotonin | 2 | 2000 | 212 | 0.070 |
Why?
|
| Cytoprotection | 1 | 2008 | 38 | 0.070 |
Why?
|
| Antipyrine | 2 | 1999 | 4 | 0.070 |
Why?
|
| Analysis of Variance | 2 | 2001 | 1008 | 0.070 |
Why?
|
| Carbon Radioisotopes | 2 | 1999 | 68 | 0.070 |
Why?
|
| Reactive Oxygen Species | 2 | 2020 | 516 | 0.070 |
Why?
|
| Drug Synergism | 1 | 2008 | 235 | 0.070 |
Why?
|
| Nitric Oxide Synthase Type II | 2 | 2005 | 92 | 0.070 |
Why?
|
| Random Allocation | 2 | 2021 | 431 | 0.070 |
Why?
|
| Protein Structure, Tertiary | 1 | 2009 | 764 | 0.070 |
Why?
|
| Ruthenium Red | 1 | 2006 | 3 | 0.070 |
Why?
|
| Carotid Arteries | 1 | 2007 | 135 | 0.060 |
Why?
|
| Manganese | 1 | 2006 | 58 | 0.060 |
Why?
|
| Brimonidine Tartrate | 2 | 1996 | 3 | 0.060 |
Why?
|
| Hyperhomocysteinemia | 1 | 2005 | 37 | 0.060 |
Why?
|
| DNA Primers | 1 | 2006 | 636 | 0.060 |
Why?
|
| Sleep Stages | 1 | 2025 | 34 | 0.060 |
Why?
|
| Miconazole | 1 | 2005 | 2 | 0.060 |
Why?
|
| Lipoxygenase | 1 | 2005 | 3 | 0.060 |
Why?
|
| Hippocampus | 1 | 2010 | 820 | 0.060 |
Why?
|
| Phosphorylation | 1 | 2009 | 1612 | 0.060 |
Why?
|
| Protein Kinase C | 1 | 2005 | 120 | 0.060 |
Why?
|
| Species Specificity | 1 | 2006 | 542 | 0.060 |
Why?
|
| Kynurenine | 1 | 2025 | 26 | 0.060 |
Why?
|
| Feedback | 1 | 2006 | 166 | 0.060 |
Why?
|
| Amides | 1 | 2005 | 91 | 0.060 |
Why?
|
| Oxidoreductases | 1 | 2005 | 101 | 0.060 |
Why?
|
| Cromolyn Sodium | 1 | 2023 | 5 | 0.050 |
Why?
|
| Muscle, Skeletal | 2 | 2001 | 1037 | 0.050 |
Why?
|
| Actins | 1 | 2006 | 334 | 0.050 |
Why?
|
| Infarction, Middle Cerebral Artery | 1 | 2023 | 36 | 0.050 |
Why?
|
| Mucins | 1 | 2023 | 72 | 0.050 |
Why?
|
| Ligands | 1 | 2025 | 495 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 1285 | 0.050 |
Why?
|
| Muscle Tonus | 2 | 2002 | 5 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 1 | 2006 | 1555 | 0.050 |
Why?
|
| Nerve Tissue Proteins | 1 | 2009 | 1134 | 0.050 |
Why?
|
| 5,8,11,14-Eicosatetraynoic Acid | 1 | 2002 | 2 | 0.050 |
Why?
|
| Female | 8 | 2025 | 70787 | 0.050 |
Why?
|
| Antioxidants | 2 | 2005 | 333 | 0.050 |
Why?
|
| Capillaries | 1 | 2003 | 71 | 0.050 |
Why?
|
| Arachidonic Acids | 1 | 2002 | 29 | 0.050 |
Why?
|
| Interleukin-17 | 1 | 2023 | 129 | 0.050 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2025 | 380 | 0.050 |
Why?
|
| Tryptophan | 1 | 2022 | 94 | 0.050 |
Why?
|
| Isoenzymes | 1 | 2002 | 222 | 0.050 |
Why?
|
| Gray Matter | 1 | 2022 | 44 | 0.050 |
Why?
|
| Middle Aged | 4 | 2025 | 29021 | 0.050 |
Why?
|
| 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt | 1 | 2001 | 1 | 0.040 |
Why?
|
| Cytoplasm | 1 | 2002 | 269 | 0.040 |
Why?
|
| Models, Cardiovascular | 1 | 2002 | 183 | 0.040 |
Why?
|
| Platelet Membrane Glycoproteins | 1 | 2001 | 30 | 0.040 |
Why?
|
| Integrin beta3 | 1 | 2001 | 29 | 0.040 |
Why?
|
| Oleanolic Acid | 1 | 2021 | 8 | 0.040 |
Why?
|
| Dilatation, Pathologic | 1 | 2001 | 89 | 0.040 |
Why?
|
| Estradiol | 1 | 2023 | 488 | 0.040 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 3761 | 0.040 |
Why?
|
| Cholic Acid | 1 | 2021 | 19 | 0.040 |
Why?
|
| Iloprost | 1 | 2001 | 7 | 0.040 |
Why?
|
| Cecum | 1 | 2021 | 28 | 0.040 |
Why?
|
| Receptors, Neuropeptide Y | 1 | 2001 | 8 | 0.040 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2021 | 60 | 0.040 |
Why?
|
| Ouabain | 1 | 2000 | 22 | 0.040 |
Why?
|
| Hypertonic Solutions | 1 | 2000 | 20 | 0.040 |
Why?
|
| Severity of Illness Index | 2 | 2014 | 3093 | 0.040 |
Why?
|
| Oligopeptides | 1 | 2001 | 115 | 0.040 |
Why?
|
| Sucrose | 1 | 2000 | 37 | 0.040 |
Why?
|
| Scavenger Receptors, Class E | 1 | 2020 | 9 | 0.040 |
Why?
|
| Osmolar Concentration | 1 | 2000 | 156 | 0.040 |
Why?
|
| Neurons | 1 | 2010 | 2015 | 0.040 |
Why?
|
| Clathrin | 1 | 2020 | 24 | 0.040 |
Why?
|
| Phenyl Ethers | 1 | 2020 | 12 | 0.040 |
Why?
|
| Gases | 1 | 2000 | 20 | 0.040 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2020 | 56 | 0.040 |
Why?
|
| Ischemia | 1 | 2023 | 371 | 0.040 |
Why?
|
| Phenotype | 1 | 2010 | 4540 | 0.040 |
Why?
|
| Antigen-Presenting Cells | 1 | 2020 | 133 | 0.040 |
Why?
|
| Endocytosis | 1 | 2020 | 126 | 0.040 |
Why?
|
| Antibodies | 1 | 2001 | 366 | 0.040 |
Why?
|
| Cell Death | 1 | 2020 | 243 | 0.040 |
Why?
|
| Tetraethylammonium | 1 | 1999 | 11 | 0.040 |
Why?
|
| Apamin | 1 | 1999 | 4 | 0.040 |
Why?
|
| 4-Aminopyridine | 1 | 1999 | 29 | 0.040 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2000 | 119 | 0.040 |
Why?
|
| NIH 3T3 Cells | 1 | 2019 | 96 | 0.040 |
Why?
|
| Receptors, Purinergic P2Y1 | 1 | 1999 | 10 | 0.040 |
Why?
|
| Antigens, CD | 1 | 2001 | 436 | 0.040 |
Why?
|
| Whole Genome Sequencing | 1 | 2021 | 327 | 0.040 |
Why?
|
| Least-Squares Analysis | 1 | 1998 | 34 | 0.040 |
Why?
|
| Carotid Artery Diseases | 1 | 2000 | 137 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2020 | 13027 | 0.040 |
Why?
|
| Catalytic Domain | 1 | 2019 | 179 | 0.040 |
Why?
|
| Polyethylene Glycols | 1 | 2000 | 251 | 0.040 |
Why?
|
| Intestinal Mucosa | 1 | 2023 | 797 | 0.040 |
Why?
|
| Bile Acids and Salts | 1 | 2021 | 255 | 0.040 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2021 | 304 | 0.040 |
Why?
|
| KATP Channels | 1 | 1998 | 11 | 0.040 |
Why?
|
| Egtazic Acid | 1 | 1998 | 19 | 0.040 |
Why?
|
| Exploratory Behavior | 1 | 2018 | 55 | 0.040 |
Why?
|
| Nitroarginine | 1 | 1998 | 8 | 0.040 |
Why?
|
| Cesium | 1 | 1998 | 11 | 0.040 |
Why?
|
| Receptors, Purinergic P2Y12 | 1 | 2017 | 5 | 0.040 |
Why?
|
| Cell Surface Extensions | 1 | 2017 | 7 | 0.040 |
Why?
|
| NF-kappa B | 1 | 2020 | 454 | 0.030 |
Why?
|
| Coronary Vessels | 1 | 2022 | 549 | 0.030 |
Why?
|
| Functional Laterality | 1 | 1998 | 195 | 0.030 |
Why?
|
| Purinergic P2 Receptor Agonists | 1 | 1997 | 2 | 0.030 |
Why?
|
| Neurologic Examination | 1 | 2018 | 202 | 0.030 |
Why?
|
| Muscle Strength | 1 | 2018 | 86 | 0.030 |
Why?
|
| Thionucleosides | 1 | 1997 | 6 | 0.030 |
Why?
|
| Cell Shape | 1 | 2017 | 69 | 0.030 |
Why?
|
| Chemotaxis | 1 | 2017 | 62 | 0.030 |
Why?
|
| Cells, Cultured | 2 | 2019 | 3046 | 0.030 |
Why?
|
| Adenine Nucleotides | 1 | 1997 | 36 | 0.030 |
Why?
|
| Reference Values | 2 | 2014 | 703 | 0.030 |
Why?
|
| Indazoles | 1 | 1997 | 31 | 0.030 |
Why?
|
| HeLa Cells | 1 | 2019 | 731 | 0.030 |
Why?
|
| Cell Polarity | 1 | 2017 | 125 | 0.030 |
Why?
|
| Peptide Fragments | 1 | 2001 | 800 | 0.030 |
Why?
|
| Neuropsychological Tests | 1 | 2021 | 990 | 0.030 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 1998 | 197 | 0.030 |
Why?
|
| Electric Stimulation | 1 | 1997 | 250 | 0.030 |
Why?
|
| Nervous System | 1 | 1997 | 127 | 0.030 |
Why?
|
| Idazoxan | 1 | 1996 | 1 | 0.030 |
Why?
|
| Dioxanes | 1 | 1996 | 4 | 0.030 |
Why?
|
| Adenosine | 1 | 1997 | 135 | 0.030 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2020 | 694 | 0.030 |
Why?
|
| Systole | 1 | 2016 | 205 | 0.030 |
Why?
|
| Linear Models | 1 | 1998 | 714 | 0.030 |
Why?
|
| Biodiversity | 1 | 2016 | 87 | 0.030 |
Why?
|
| Wounds and Injuries | 1 | 2000 | 394 | 0.030 |
Why?
|
| Inflammasomes | 1 | 2017 | 166 | 0.030 |
Why?
|
| Iofetamine | 1 | 1995 | 1 | 0.030 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 1995 | 19 | 0.030 |
Why?
|
| Amphetamines | 1 | 1995 | 9 | 0.030 |
Why?
|
| GTP-Binding Proteins | 1 | 1996 | 172 | 0.030 |
Why?
|
| Autoradiography | 1 | 1995 | 67 | 0.030 |
Why?
|
| Imidazoles | 1 | 1996 | 219 | 0.030 |
Why?
|
| Ischemic Attack, Transient | 1 | 1995 | 64 | 0.030 |
Why?
|
| Macrophages, Alveolar | 1 | 2014 | 47 | 0.030 |
Why?
|
| Aged | 2 | 2025 | 21482 | 0.030 |
Why?
|
| Rats, Wistar | 1 | 1995 | 329 | 0.030 |
Why?
|
| United States | 2 | 2020 | 11669 | 0.030 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2014 | 149 | 0.030 |
Why?
|
| Comorbidity | 1 | 2019 | 1610 | 0.030 |
Why?
|
| Dementia | 1 | 2019 | 475 | 0.030 |
Why?
|
| Phylogeny | 1 | 2016 | 763 | 0.030 |
Why?
|
| Cell Movement | 1 | 2017 | 891 | 0.030 |
Why?
|
| Cell Line | 1 | 2019 | 2724 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2014 | 364 | 0.030 |
Why?
|
| Age Factors | 1 | 2018 | 2923 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2019 | 3691 | 0.020 |
Why?
|
| Respiration, Artificial | 1 | 2014 | 504 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2001 | 1829 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 5410 | 0.020 |
Why?
|
| Transcriptome | 1 | 2017 | 1125 | 0.020 |
Why?
|
| Heart Rate | 1 | 1994 | 584 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2013 | 881 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2020 | 7138 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2013 | 1423 | 0.020 |
Why?
|
| Young Adult | 1 | 2022 | 9966 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2013 | 2680 | 0.020 |
Why?
|
| Pterins | 1 | 2005 | 6 | 0.020 |
Why?
|
| Cystathionine beta-Synthase | 1 | 2005 | 14 | 0.020 |
Why?
|
| Glutathione Peroxidase | 1 | 2005 | 47 | 0.010 |
Why?
|
| Lung | 1 | 2013 | 1556 | 0.010 |
Why?
|
| Homocysteine | 1 | 2005 | 120 | 0.010 |
Why?
|
| Risk Factors | 1 | 2019 | 10945 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2014 | 3736 | 0.010 |
Why?
|
| Mice, Mutant Strains | 1 | 2005 | 377 | 0.010 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2005 | 246 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2005 | 618 | 0.010 |
Why?
|
| Partial Pressure | 1 | 2000 | 28 | 0.010 |
Why?
|
| Muscle Fatigue | 1 | 2000 | 7 | 0.010 |
Why?
|
| Parietal Lobe | 1 | 2000 | 48 | 0.010 |
Why?
|
| Chimera | 1 | 2000 | 83 | 0.010 |
Why?
|
| Adult | 1 | 2020 | 31614 | 0.010 |
Why?
|
| Diaphragm | 1 | 2000 | 98 | 0.010 |
Why?
|
| Heterozygote | 1 | 2000 | 715 | 0.010 |
Why?
|
| Oxygen | 1 | 2000 | 569 | 0.010 |
Why?
|
| Mutation | 1 | 2000 | 6250 | 0.000 |
Why?
|